Patients with melanomas containing activating mutations in KIT have been reported to respond to imatinib therapy (Lutzky et al, 2008; Quintas-Cardama et al, 2008; Satzger et al, 2010); however, it remains uncertain whether mutations considered to be predictive of imatinib resistance can respond to second-generation KIT kinase inhibitors. The gene discussed is KIT; the disease is melanoma.